No title
Abstract in Danish Infliximab er effektiv ved reumatoid artritis (RA), men behandlingssvigt er hyppige. Sera fra 106 RA-patienter monitoreredes med en radioimmunoassay (RIA) for funktionel infliximab og en RIA for anti-infliximab-antistof. S-infliximab varierede betydeligt, f.eks. 0-22 μg/ml forud for tredje infusion, og efter seks måneder var 44% antistofpositive. Lav S-infliximab var forbundet mRemicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and l